Preferred Label : sparsentan;

MeSH Hyperonym : (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-; 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide;

UNII : 9242RO5URM;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/filspari
2024
false
false
false
Netherlands
French
English
drug approval
europe
sparsentan
sparsentan
orphan drug production
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
adult
glomerulonephritis, iga
Primary immunoglobulin A nephropathy (disorder)
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
Endothelin A Receptor Antagonists
Endothelin A Receptor Antagonists
angiotensin II receptor antagonists
angiotensin II receptor antagonists
drug evaluation, preclinical
sparsentan

---
https://www.has-sante.fr/jcms/p_3562970/fr/filspari-sparsentan-nephropathie-a-immunoglobulines-a-primitive-n-iga
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Primary immunoglobulin A nephropathy (disorder)
angiotensin receptor antagonists
Endothelin A Receptor Antagonists
administration, oral
adult
orphan drug production
sparsentan
evaluation of the transparency committee
sparsentan
glomerulonephritis, iga

---
https://www.has-sante.fr/jcms/p_3543060/fr/filspari-sparsentan-nephropathie-a-iga-primitive
2024
false
false
false
France
Primary immunoglobulin A nephropathy (disorder)
treatment outcome
insurance, health, reimbursement
Endothelin A Receptor Antagonists
angiotensin II receptor antagonists
administration, oral
sparsentan
evaluation of the transparency committee
glomerulonephritis, iga
sparsentan

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.